Evogene Ltd. Reports Q4 and FY 2023 Financial Results
Ticker: EVGN · Form: 6-K · Filed: Mar 7, 2024 · CIK: 1574565
Sentiment: neutral
Topics: financial-results, earnings
TL;DR
Evogene dropped its Q4 and FY23 earnings report on March 7th.
AI Summary
Evogene Ltd. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023, on March 7, 2024. The company, incorporated in Israel, is involved in agriculture chemicals.
Why It Matters
This filing provides investors with an update on Evogene's financial performance for the past fiscal year, crucial for assessing the company's stability and growth prospects.
Risk Assessment
Risk Level: low — This is a routine financial results filing with no new material events or significant changes indicated.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- March 7, 2024 (date) — Announcement date of financial results
- December 31, 2023 (date) — Fiscal year end date
- 001-36187 (company) — SEC File Number
FAQ
What is the primary business of Evogene Ltd.?
Evogene Ltd. is primarily involved in agriculture chemicals, as indicated by its SIC code.
When were the financial results for the fourth quarter and fiscal year ended December 31, 2023, announced?
The financial results were announced on March 7, 2024.
What form is this SEC filing?
This SEC filing is a Form 6-K.
Under which act is this report filed?
This report is filed under the 1934 Act.
Where is Evogene Ltd. headquartered?
Evogene Ltd. is headquartered at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel.
Filing Stats: 291 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2024-03-07 07:00:17
Filing Documents
- zk2431110.htm (6-K) — 11KB
- exhibit_99-1.htm (EX-99.1) — 448KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001178913-24-000857.txt ( ) — 466KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On March 7, 2024, Evogene Ltd. (" Evogene ") announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this " Form 6-K ") and is incorporated herein by reference. The GAAP financial statements tables contained in the press release attached to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (" SEC ") File Nos. 333-253300 and 333-277565), and Form S-8 (SEC File Nos. 333-259215, 333-193788, 333-201443 and 333-203856) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: March 7, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release: Evogene Reports Fourth Quarter and Full Year 2023 Financial Results.